ClinicalTrials.gov
public full text
Public Domain
GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes
This 15-19 week study is being conducted by GW Pharma Ltd as a pilot study in order to determine the efficacy and safety of two cannabinoids: GWP42004 and GWP42003 alone, or in combination in patients with Type 2 diabetes. This is the first study to determine whether the study medications have a positive benefit for subjects on their cholesterol levels, body weight, liver fat content and other metabolic parameters compared with a placebo medication.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of Cannabidiol (CBD) in Healthy Volunteers#1139759
- The Effect of Cannabis on Dementia Related Agitation and Aggression#1044213
- Alcohol Use Disorder and Cannabidiol#908546
- Sex differences in plasma endocannabinoids and related lipids before and after single and repeated mTBI: an exploratory study of endolipid plasma biomarkers.#338320
- Effects of Cannabis Administration Routes on Human Performance and Pharmacokinetics#1089058
Record · ID 1030822
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive